Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute is a promising company, with a strong focus on developing therapies for rare and metabolic diseases such as congenital hyperinsulinism. Despite missing key endpoints in the phase 2b trial for their lead drug candidate, ersodetug, the company has implemented a streamlined phase 3 trial protocol for the drug in the tumor HI indication, which is currently enrolling patients. The company has sufficient cash to carry out this trial and potentially bring ersodetug to market for this patient population, while also exploring its potential in other indications.

Bears say

Rezolute is a biopharmaceutical company that is developing promising therapies for rare and metabolic diseases, with a focus on congenital hyperinsulinism and tumor-induced hyperinsulinism. However, there are significant risks associated with the company, including its financial standing and the need for additional capital, as well as potential competition and regulatory hurdles that could delay the approval of their products. As a financial analyst, the negative outlook on Rezolute's stock is based on the current lack of generated revenue, high capital needs, and the uncertainties and challenges that lie ahead for the company to successfully bring their therapies to market.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.